4.6 Review

Project Harmony: A Systematic Review and Network Meta-Analysis of Psychotherapy and Pharmacologic Trials for Comorbid Posttraumatic Stress, Alcohol, and Other Drug Use Disorders

Journal

PSYCHOLOGICAL BULLETIN
Volume -, Issue -, Pages -

Publisher

AMER PSYCHOLOGICAL ASSOC
DOI: 10.1037/bul0000409

Keywords

alcohol and other drug use disorders; systematic review; network meta-analysis; clinical interventions; posttraumatic stress disorder comorbidity

Ask authors/readers for more resources

This study conducted a systematic review and network meta-analyses to examine the effects of psychotherapy and pharmacologic treatments for individuals with co-occurring posttraumatic stress disorder (PTSD) and alcohol or other drug use disorder (AOD). The findings indicate that integrated, trauma-focused therapy shows greater effectiveness in reducing PTSD symptoms compared to other therapies, while AOD medication is more effective in reducing alcohol use severity.
We conducted a systematic review and network meta-analyses (NMA) of psychotherapy and pharmacologic treatments for individuals with co-occurring posttraumatic stress disorder (PTSD) and alcohol or other drug use disorder (AOD). A comprehensive search spanning 1995-2019 yielded a pool of 39 studies for systematic review, including 24 randomized controlled trials for the NMA. Study interventions were grouped by target of treatment (PTSD + AOD, PTSD-only, and AOD-only) and approach (psychotherapy or medication). Standardized mean differences (SMD) from the NMA yielded evidence that at the end of treatment, integrated, trauma-focused therapy for PTSD + AOD was more effective at reducing PTSD symptoms than integrated, non-trauma-focused therapy (SMD = -0.30), AOD-focused psychotherapy (SMD = -0.29), and other control psychotherapies (SMD = -0.43). End-of-treatment alcohol use severity was less for AOD medication compared to placebo medication (SMD = -0.36) and trauma-focused therapy for PTSD + placebo medication (SMD = -0.67), and less for trauma-focused psychotherapy + AOD medication compared to PTSD medication (SMD = -0.53), placebo medication (SMD = -0.50), and trauma-focused psychotherapy + placebo medication (SMD = -0.81). Key limitations include the small number of studies in the NMA for pharmacologic treatments and the lack of demographic diversity apparent in the existing literature. Findings suggest room for new studies that can address limitations in study sample composition, sample sizes, retention, and apply new techniques for conducting comparative effectiveness in PTSD + AOD treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available